Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel

Zhengwang Zhang, Jennifer Stanfield, Eugene Frenkel, Wareef Kabbani, Jer Tsong Hsieh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: To study whether a histone deacetylase inhibitor, FK228, can enhance therapeutic efficacies of other chemotherapeutic agents against androgen-independent prostate cancer (AIPCa) and to explore any possible early biomarker for predicting drug response. Methods: The therapeutic effects of FK228-based combinations on three AIPCa cell lines (PC-3, DU145, and C4-2) were evaluated by synergisms of cytotoxicity. Cell cycle analysis and Western blot assay were used to study the underlying mechanisms of drug action and search for any potential surrogate biomarker. In addition, we investigated the in vivo antitumor effects of the FK228/docetaxel combination using the PC-3 xenograft model. Results: FK228/docetaxel surpassed other FK228-based combinations by achieving more synergism of cytotoxicity. FK228 enhanced the therapeutic effect of docetaxel against AIPCa by exhibiting markedly enhanced and prolonged inhibitory effects in vitro and better tumor regression in vivo by inducing apoptosis. It appears that p21WAF1 induction consistently correlates with single or combination treatment. Conclusions: The results of our study have shown that FK228 is able to enhance the therapeutic effect of docetaxel against AIPCa. FK228 appears to be a promising second-line option in combination with docetaxel. The p21WAF1 protein level can be used as a surrogate biomarker to predict and monitor the therapeutic response.

Original languageEnglish (US)
Pages (from-to)396-401
Number of pages6
JournalUrology
Volume70
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

docetaxel
Depsipeptides
Histone Deacetylase Inhibitors
Therapeutic Uses
Androgens
Prostatic Neoplasms
Pharmacological Biomarkers
Biomarkers
romidepsin
Heterografts

ASJC Scopus subject areas

  • Urology

Cite this

Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel. / Zhang, Zhengwang; Stanfield, Jennifer; Frenkel, Eugene; Kabbani, Wareef; Hsieh, Jer Tsong.

In: Urology, Vol. 70, No. 2, 08.2007, p. 396-401.

Research output: Contribution to journalArticle

Zhang, Zhengwang ; Stanfield, Jennifer ; Frenkel, Eugene ; Kabbani, Wareef ; Hsieh, Jer Tsong. / Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel. In: Urology. 2007 ; Vol. 70, No. 2. pp. 396-401.
@article{889e712438714704b1fc27f86ea7735e,
title = "Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel",
abstract = "Objectives: To study whether a histone deacetylase inhibitor, FK228, can enhance therapeutic efficacies of other chemotherapeutic agents against androgen-independent prostate cancer (AIPCa) and to explore any possible early biomarker for predicting drug response. Methods: The therapeutic effects of FK228-based combinations on three AIPCa cell lines (PC-3, DU145, and C4-2) were evaluated by synergisms of cytotoxicity. Cell cycle analysis and Western blot assay were used to study the underlying mechanisms of drug action and search for any potential surrogate biomarker. In addition, we investigated the in vivo antitumor effects of the FK228/docetaxel combination using the PC-3 xenograft model. Results: FK228/docetaxel surpassed other FK228-based combinations by achieving more synergism of cytotoxicity. FK228 enhanced the therapeutic effect of docetaxel against AIPCa by exhibiting markedly enhanced and prolonged inhibitory effects in vitro and better tumor regression in vivo by inducing apoptosis. It appears that p21WAF1 induction consistently correlates with single or combination treatment. Conclusions: The results of our study have shown that FK228 is able to enhance the therapeutic effect of docetaxel against AIPCa. FK228 appears to be a promising second-line option in combination with docetaxel. The p21WAF1 protein level can be used as a surrogate biomarker to predict and monitor the therapeutic response.",
author = "Zhengwang Zhang and Jennifer Stanfield and Eugene Frenkel and Wareef Kabbani and Hsieh, {Jer Tsong}",
year = "2007",
month = "8",
doi = "10.1016/j.urology.2007.03.052",
language = "English (US)",
volume = "70",
pages = "396--401",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel

AU - Zhang, Zhengwang

AU - Stanfield, Jennifer

AU - Frenkel, Eugene

AU - Kabbani, Wareef

AU - Hsieh, Jer Tsong

PY - 2007/8

Y1 - 2007/8

N2 - Objectives: To study whether a histone deacetylase inhibitor, FK228, can enhance therapeutic efficacies of other chemotherapeutic agents against androgen-independent prostate cancer (AIPCa) and to explore any possible early biomarker for predicting drug response. Methods: The therapeutic effects of FK228-based combinations on three AIPCa cell lines (PC-3, DU145, and C4-2) were evaluated by synergisms of cytotoxicity. Cell cycle analysis and Western blot assay were used to study the underlying mechanisms of drug action and search for any potential surrogate biomarker. In addition, we investigated the in vivo antitumor effects of the FK228/docetaxel combination using the PC-3 xenograft model. Results: FK228/docetaxel surpassed other FK228-based combinations by achieving more synergism of cytotoxicity. FK228 enhanced the therapeutic effect of docetaxel against AIPCa by exhibiting markedly enhanced and prolonged inhibitory effects in vitro and better tumor regression in vivo by inducing apoptosis. It appears that p21WAF1 induction consistently correlates with single or combination treatment. Conclusions: The results of our study have shown that FK228 is able to enhance the therapeutic effect of docetaxel against AIPCa. FK228 appears to be a promising second-line option in combination with docetaxel. The p21WAF1 protein level can be used as a surrogate biomarker to predict and monitor the therapeutic response.

AB - Objectives: To study whether a histone deacetylase inhibitor, FK228, can enhance therapeutic efficacies of other chemotherapeutic agents against androgen-independent prostate cancer (AIPCa) and to explore any possible early biomarker for predicting drug response. Methods: The therapeutic effects of FK228-based combinations on three AIPCa cell lines (PC-3, DU145, and C4-2) were evaluated by synergisms of cytotoxicity. Cell cycle analysis and Western blot assay were used to study the underlying mechanisms of drug action and search for any potential surrogate biomarker. In addition, we investigated the in vivo antitumor effects of the FK228/docetaxel combination using the PC-3 xenograft model. Results: FK228/docetaxel surpassed other FK228-based combinations by achieving more synergism of cytotoxicity. FK228 enhanced the therapeutic effect of docetaxel against AIPCa by exhibiting markedly enhanced and prolonged inhibitory effects in vitro and better tumor regression in vivo by inducing apoptosis. It appears that p21WAF1 induction consistently correlates with single or combination treatment. Conclusions: The results of our study have shown that FK228 is able to enhance the therapeutic effect of docetaxel against AIPCa. FK228 appears to be a promising second-line option in combination with docetaxel. The p21WAF1 protein level can be used as a surrogate biomarker to predict and monitor the therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=34548438593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548438593&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.03.052

DO - 10.1016/j.urology.2007.03.052

M3 - Article

C2 - 17826527

AN - SCOPUS:34548438593

VL - 70

SP - 396

EP - 401

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -